# CSL Behring acquires global commercialization rights to uniQure's hemophilia B gene therapy AMT-061

CSL Behring acquired exclusive global rights to commercialize AMT-061, a gene therapy for hemophilia B, from uniQure. uniQure will receive an upfront payment of $450 million and additional royalties.

- Type: Contract
- Announced: 2020-06-25
- Value: $450.0M
- Status: announced
- Products: AMT-061 gene therapy for hemophilia B
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CSL Behring](https://endata.com/companies/28726.md) (customer)
- [UniQure](https://endata.com/companies/48119.md) (supplier)

## Sources

- [hemophilianewstoday.com](https://hemophilianewstoday.com/news/csl-behring-acquires-commercial-rights-amt-061-hemophilia-b-gene-therapy-from-uniqure/), 2020-06-25: "We are thrilled to enter into this commercialization and license agreement with CSL Behring, an ideal commercial partner with global reach and decades of expertise in hemophilia."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.